Novel potent and selective P2Y1 purinergic receptor antagonist.

Potent, Orally Bioavailable, Metabolically Stable Thumb Site 1 Inhibitor of the Hepatitis C Virus NS5B RNA-Dependent, RNA Polymerase

Novel potent antagonist of corticotropin-releasing factor/hormone receptor 1 (CRHR-1)

Novel potent antagonist of corticotropin-releasing factor/hormone receptor 1 (CRHR-1)

Novel Novel γ-secretase modulator, decreasing Aß1-40 and Aß1-42 and increasing Aß1-37 and Aß1-38 in rat brain modulator, decreasing Aß1-40 and Aß1-42 and increasing Aß1-37 and Aß1-38 in rat brain

Novel potent antagonist of corticotropin-releasing factor/hormone receptor 1 (CRHR-1)

Novel Inhibitor of human immunodeficiency virus type 1 (HIV-1) attachment

Novel, potent, exceptionally selective inhibitor of TNF-α Converting Enzyme (TACE)

Potent and selective dipeptidyl peptidase IV (DPP-IV) inhibitor

Novel Inhibitor of human immunodeficiency virus type 1 (HIV-1) attachment

Prodrug of the novel fluoro-substituted camptothecin analog, BMS-286309

Novel Selective CYP17A1 Lyase Inhibitor

Novel dissociated glucocorticoid receptor modulator

Novel fluoro-substituted camptothecin, inducing topoisomerase I-mediated DNA breaks

Highly potent and selective phosphodiesterase 5 (PDE 5) inhibitor

Potent and selective beta-lactam tryptase inhibitor, inhibiting factor XIa and producing antithrombotic efficacy with minimal bleeding time prolongation

Selective ATP hydrolase inhibitor

Potent and selective p56(lck) inhibitor

Potent and selective β3 full agonist

Novel potent inhibitor of the ATP hydrolase activity of mitochondrial F1F0 ATP synthase

Novel and selective neuropeptide Y1 receptor antagonist

Retinoic acid receptor (RAR) pan-antagonist

Squalene synthase inhibitor

Quantity (mg or Unit) Unit Price ($/mg or $/Unit) Final Price 100 $13.95 Total: $1,395.00 50 $16.12 Total: $806.00 25 $18.91 Total: $472.75 10 $22.32 Total: $223.20 5 $26.35 Total: $131.75

Novel antifungal and fungicidal agent

Novel K channel opener; Glyburide-Reversible Cardioprotective Agent with Minimal Vasodilator Activity

5HT1B/1D agonist

Novel potent, selective inhibitor of AAK1 (adaptor associated kinase 1), having the appropriate combination of solubility and charge required for microiontophoresis

Novel PD-1/PD-L1 Inhibitor

Novel PD-L1 Inhibitor